{"id":551,"date":"2001-03-01T12:05:00","date_gmt":"2001-03-01T11:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie"},"modified":"2022-03-17T14:09:47","modified_gmt":"2022-03-17T13:09:47","slug":"eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie","title":{"rendered":"Eptifibatid bei koronaren Stent-Implantationen. Die ESPRIT-Studie"},"content":{"rendered":"<p>Unmittelbar vor und 3-4 Wochen nach einer koronaren Ballondilatation (Perkutane transluminale koronare Angioplastie = PTCA) mit Stent-Implantation wird heute eine Pharmakotherapie mit Azetylsalizyls\u00e4ure (ASS) und einem Thienopyridin (Ticlopidin = z.B. Tiklyd, Clopidogrel = Plavix, Iscover ) zur Prophylaxe einer Restenose empfohlen. In bestimmten Risikosituationen (z.B. akuter Myokardinfarkt, instabile Angina pectoris) wird zus\u00e4tzlich ein GP-IIb\/IIIa-Blocker (z.B. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Unmittelbar vor und 3-4 Wochen nach einer koronaren Ballondilatation (Perkutane transluminale koronare Angioplastie = PTCA) mit Stent-Implantation wird heute eine Pharmakotherapie mit Azetylsalizyls\u00e4ure (ASS) und einem Thienopyridin (Ticlopidin = z.B. Tiklyd, Clopidogrel = Plavix, Iscover ) zur Prophylaxe einer Restenose empfohlen. In bestimmten Risikosituationen (z.B. akuter Myokardinfarkt, instabile Angina pectoris) wird zus\u00e4tzlich ein GP-IIb\/IIIa-Blocker (z.B. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1170,1171,730,729,1172,882,727],"class_list":["post-551","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-eptifibatid","tag-esprit-studie","tag-gp-iib-iiia-rezeptor-antagonisten","tag-gp-iib-iiia-rezeptor-blocker","tag-koronar-stent","tag-stent","tag-thrombozytenaggregationshemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=551"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/551\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}